Moderna's teen COVID-19 vaccine trial hits high marks

The company should submit its request for the FDA to authorize the use of its vaccine in those 12 and older in a couple of weeks.

| More on:
A medical researcher in a white coat holds laboratory equipment and smiles.

Image source: Getty Images.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

On Tuesday, Moderna (NASDAQ: MRNA) reported highly successful results from a clinical trial of its COVID-19 vaccine in patients ages 12 to 17. Depending on how you look at the top-line data from the TeenCove study, mRNA-1273 was found to be between 93% and 100% effective at preventing new cases.

The TeenCOVE trial enrolled over 3,700 12- to 17-year-old participants. Going by the primary case definition of COVID-19, from a period starting 14 days after their second dose, none of the volunteers who received the vaccine have tested positive. And although new case numbers are plummeting across the country, four of the volunteers who received the placebo did test positive for COVID-19.

Since teenagers are far less likely to present symptoms of COVID-19 when they're infected, investigators also used a more sensitive definition of COVID-19 positivity that requires just one symptom plus a positive nasal swab test. Based on those looser criteria, the vaccine was still 93% effective at preventing new cases.

The TeenCove trial results Moderna reported Tuesday stack up nicely against those reported in March by Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) for their rival mRNA vaccine, Comirnaty. That said, comparisons between the two teen trials should be taken with a grain of salt. Pfizer and BioNTech ran their U.S.-based clinical trial in 12- to 15-year-olds at a time when far more Americans were contracting the virus.

Moderna plans to submit a completed data package from the TeenCOVE study to the FDA in early June. Given that its top-line results are roughly in line with those that earned Pfizer and BioNTech a green light for their vaccine to be administered to teens, we can reasonably expect a similar response from the regulator within a few days of its receiving Moderna's submission.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

More on International Stock News

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
International Stock News

Why Meta Platforms stock jumped 14% in June

The stock gained in two separate stages, in the beginning and end of the month.

Read more »

Zig zaggy green arrow with an American note in the background.
International Stock News

Don't overthink it — the market-beater to buy and hold for 5 years

The most dominant and profitable tech companies in the world have also been some of the best growth stocks to…

Read more »

A tech worker wearing a mask holds a computer chip.
International Stock News

Is Nvidia a good stock to buy?

The company's powerful AI-enabling graphics processing units (GPUs) are essential for the incredible AI models reshaping business and society.

Read more »

Skate board with the Google logo.
International Stock News

This artificial intelligence (AI) stock could be the best bargain in the market right now

You could argue that no topic has consumed the business world over the past couple of years quite like artificial…

Read more »

A man analyses stockmarket graph on his computer.
Share Market News

US stocks vs. ASX shares in FY25

Would you be surprised to learn that ASX tech shares rose faster than US tech stocks by almost 2:1?

Read more »

A woman in jeans and a casual jumper leans on her car and looks seriously at her mobile phone while her vehicle is charged at an electic vehicle recharging station.
International Stock News

Did Tesla just say "Checkmate" to Waymo?

Waymo commercially launched before Tesla's robotaxi, but Elon Musk's electric vehicle (EV) empire might have the last laugh.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
International Stock News

This stock is shaping the future of artificial intelligence (AI), but is it a buy right now?

The AI landscape is layered and evolving daily.

Read more »

A bright dollar sign with lights shining on it, indicating a rising dollar and positive share price movement
International Stock News

Think Nvidia Stock Is Expensive? This Chart Might Change Your Mind.

A look at both sides of the discussion.

Read more »